- Home
- EQX vs ARWR Comparison
EQX vs ARWR Comparison
Compare EQX & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQX | ARWR |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 12.4B |
| IPO Year | 2018 | 2009 |
Fundamental Metrics
Financial Performance| Metric | EQX | ARWR |
|---|---|---|
| Price | $12.85 | $82.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $17.00 | ★ $83.40 |
| AVG Volume (30 Days) | ★ 11.2M | 1.0M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.11% | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $102.84 | N/A |
| Revenue Next Year | $15.55 | N/A |
| P/E Ratio | $137.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.49 | $27.94 |
| 52 Week High | $18.96 | $95.49 |
Technical Indicators
Market Signals| Indicator | EQX | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 58.00 | 43.62 |
| Support Level | $11.94 | $82.05 |
| Resistance Level | $13.51 | $84.55 |
| Average True Range (ATR) | 0.47 | 2.89 |
| MACD | -0.13 | -0.58 |
| Stochastic Oscillator | 37.56 | 23.04 |
Price Performance
Historical ComparisonAbout EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. The company operates gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the Canada, United States, Mexico, and others. The majority of its revenue is generated from Canada.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.